Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents

详细信息    查看全文

• 作者：D. D. V. Brito (13)
  A. P. Fernandes (1)
  K. B. Gomes (1) karina@coltec.ufmg.br
  F. F. Coelho (1)
  N. G. Cruz (1)
  A. P. Sabino (1)
  J. E. Cardoso (1)
  P. P. Figueiredo-Filho (2)
  R. Diamante (2)
  C. R. Norton (2)
  M. O. Sousa (1)
• 关键词：APOA5 – ; APOE – ; Dyslipidemia – ; Children – ; Adolescents
• 刊名：Molecular Biology Reports
• 出版年：2011
• 出版时间：October 2011
• 年：2011
• 卷：38
• 期：7
• 页码：4381-4388
• 全文大小：196.6 KB
• 参考文献：1. Frohlich J, Dobi谩sov谩 M (2003) Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 49:1873–1880
  2. Mendes-Lana A, Pena GG, Freitas SN et al (2007) Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study. Braz J Med Biol Res 40:49–56
  3. American Heart Association NCEP (2004) Report implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227–239
  4. Baigent C, Keech A, Kearney PM et al (2005) Cholesterol treatment trialists’ (C-FF) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomized trials of statins. Lancet 366:267–278
  5. Pennacchio LA, Olivier M, Hubacek JA et al (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173
  6. Volcik KA, Barkley RA, Hutchinson RG et al (2006) Apolipoprotein E polymorphisms predict low-density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 164:342–348
  7. Kluger M, Heeren J, Merkel M (2008) Apoprotein A–V: an important regulator of triglyceride metabolism. J Inherit Metab Dis 31:281–288
  8. Tai ES, Ordovas JM (2008) Clinical significance of apolipoprotein A5. Curr Opin Lipidol 19:349–354
  9. Van Der Vliet HN, Sammels MG, Leegwater AC et al (2001) Apolipoprotein AV: a novel apolipoprotein associated with an early phase of liver regeneration. J Biochem 276:44512–44520
  10. Pennacchio LA, Olivier M, Hubacek RM et al (2002) Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11:3031–3038
  11. Ribalta J, Figuera L, Fernandez-Ballart J et al (2002) Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 48:1597–1600
  12. Talmud PJ, Hawe E, Martin S et al (2002) Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11:3039–3046
  13. Horinek A, Vrablik M, Ceska R, Ad谩mkov谩 V, Poledne R, Kubacek JA (2003) C-polymorphism within the apolipoprotein A–V gene in hypertriglyceridemic individuals. Atherosclerosis 167:369–370
  14. Sousa MO, Al铆a P, Pint贸 X, Corbella E, Navarro MA (2008) Interaction between APOA5–1131T>C and APOE polymorphisms and their association with severe hypertriglyceridemia. Clin Chim Acta 395:68–71
  15. AshokKumar M, Subhashini N, SaiBabu R, Ramesh A, Cherian KM, Emmanuel C (2010) Genetic variants on apolipoprotein gene cluster influence triglycerides with a risk of coronary artery disease among Indians. Mol Biol Rep 37:521–527
  16. Hubacek JA, Adamkova V, Prusikova M, Snejdrlova M et al (2009) Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics 10:945–950
  17. Eichner JE, Dunn ST, Perveen G et al (2002) Apolipoprotein E polymorphism and cardiovascular disease: a huge review. Am J Epidemiol 155:487–495
  18. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF (2008) Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambu铆 health aging study (BHAS). Braz J Med Biol Res 41:89–4194
  19. Baroni MG, Berni A, Romeo S et al (2003) Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Med Genet 4:962–968
  20. Hu P, Qin Y, Jing C, Lu L, Hu B, Du P (2010) Does the geographical gradient of apoe4 allele exist in china? A systemic comparison among multiple Chinese populations. Mol Biol Rep. doi:10.1007/s11033-010-0132-0
  21. Mahfouz R, Sabbagh A, Zahed L et al (2006) Apolipoprotein E gene polymorphism and allele frequencies in the Lebanese population. Mol Biol Rep 33:145–149
  22. Al-Khedhairy A (2004) Apolipoprotein E polymorphism in Saudis. Mol Biol Rep 31:257–260
  23. Mozas P, Castillo S, Reyes G et al (2003) Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. Am Heart J 145:999–1005
  24. Vaisi-Raygani A, Rahimi Z, Tavilani H, Pourmotabbed T (2010) Butyrylcholinesterase k variant and the apoe-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Biol Rep 37:2083–2091
  25. Bertolini S, Pisciotta L, di Scala L et al (2004) Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 174:57–65
  26. Sousa MO, Corbella E, Al铆a P, C谩mara J, Castro MJ, Pinto X, Navarro MA (2008) Aus锚ncia de associaci贸n entre el gen贸tipo de la apolipoproteina E y la respuesta al tratamiento com estatinas em los pacientes com epis贸dios isqu锚micos agudos. Med Clin (Barc) 130:401–404
  27. Rahimi Z, Vaisi-Raygani A, Pourmotabbed T (2010) Association between apolipoprotein epsilon4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in southern iran. Mol Biol Rep. doi:10.1007/s11033-010-0157-4
  28. Li Y, Tang K, Zhang Z et al. (2010) Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis. Mol Biol Rep. doi:10.1007/s11033-010-9999-z
  29. Hubacek JA, Horinek A, Skodova Z, Adamkova V, Poledne R (2007) Sex specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur J Hum Genet 16:135–138
  30. SBC-Brazilian Society of Cardiology (2005) I Guidelines for the prevention of atherosclerosis in childhood and adolescence. Arq Bras Cardiol 85:4–36
  31. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
  32. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548
  33. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci 100:177–182
  34. Evans D, Buchwald A, Beil FU (2003) The single nucleotide polymorphism −1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipemia. J Mol Med 81:645–654
  35. Moreno-Luna R, Perez-Jimenez F, Marin C et al (2007) Two independent apolipoprotein A5 haplotypes module post-prandial lipoprotein metabolism in a healthy Caucasian population. J Endocrin Metab 92:2280–2285
  36. Nabika T, Nasreen S, Kobayashi S, Masuda J (2002) The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 165:201–204
  37. Bi N, Yan SK, Li GP, Yin ZN, Chen BS (2004) A single nucleotide polymorphism −1131T>C in the apolipoprotein A5 gene is associated with a increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol Genet Metab 83:280–286
  38. Hsu LA, Ko YL, Chang CJ et al (2006) Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 185:143–149
  39. Matsunaga A, Arishima H, Nijmura H et al (2007) Strong linkage disequilibrium and association of −1131T>C and c.553G>T polymorphisms of the apolipoprotein A5 gene with hypertriglyceridemia in a Japanese population. Circ J 71:746–752
  40. Pitsavos C, Choumerianou DM, Skoumas J et al (2005) Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolemia. Clin Exp Med 5:196–201
  41. Giassakis G, Veletza S, Papanas N, Heliopoulos I, Piperidou H (2007) Apolipoprotein E and first-ever ischaemic stroke in Greek hospitalized patients. J Int Med Res 35:127–133
  42. Gr枚nroos P, Raitakari OT, K盲h枚nen M et al (2007) Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein chances: a 21-year follow-up study from childhood to adulthood. The cardiovascular risk in young Finns study. Clin Chem Lab Med 45:592–598
  43. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF (2007) Apolipoprotein E polymorphism distribution in an elderly Brazilian population: the Bambu铆 health and aging study. Braz J Med Biol Res 40:1429–1434
  44. Bazrgar M, Karimi M, Fathzadeh M et al (2008) Apolipoprotein E polymorphism in Southern Iran: E4 allele in the lowest reported amounts. Mol Biol Rep 35:495–499
  45. Fran莽a E, Alves JGB, Hutz MH (2004) Apolipoprotein E polymorphism and its association with serum lipid levels in Brazilian children. Hum Biol 76:267–275
  46. Fiegenbaum M, Andrade FM, Hutz MH (2007) Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APO E genotypes. Clin Chim Acta 380:175–181
  47. Svobodov谩 H, Kucera F, Stulc T et al (2007) Apolipoprotein E gene polymorphism in the Mongolian population. Folia Biol (Praha) 53:138–142
  48. Gran茅r M, Kahri J, Varpula M et al (2008) Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 18:271–277
  49. Saidi S, Slamia LB, Ammou SB, Mahjoub T, Almawi WY (2007) Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. J Stroke Cerebrovasc Dis 16:160–166
  50. Jang Y, Paik JK, Hyun JY et al (2009) The apolipoprotein A5–1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta 402:83–87
  51. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S (2002) Association found between the promoter region polymorphism in the apolipoprotein A–V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 111:570–572
  52. Charriere S, Bernard S, Aqallal M et al (2008) Association of APOA5–1131T>C and S19 W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients. Clin Chim Acta 394:99–103
  53. Srinivasan SR, Ehnholm C, Wattigney W, Berenson GS (1993) Apolipoprotein E polymorphism and its association with serum lipoprotein concentrations in black versus white children: the Bogalusa Heart Study. Metabolism 42:381–386
  54. Callas N, Poveda E, Baracaldo C, Hern谩ndez P, Castillo C, Guerra M (2007) Polimorfismo gen茅tico de la apolipoprote铆na E en un grupo de escolares del centro-oriente colombiano: comparaci贸n con las concentraciones plasm谩ticas de l铆pidos y apolipoprote铆nas. Biom茅dica 27:526–536
  55. Souza DRS, Nakachima L, Biagioni RB et al (2007) Relevance of apolipoprotein E4 for the lipid profile of Brazilian patients with coronary artery disease. Braz J Med Biol Res 40:189–197
  56. Liang S, Pan M, Geng H et al (2009) Apolipoprotein E polymorphism in normal Han Chinese population: frequency and effect on lipid parameters. Mol Biol Rep 36:1251–1256
  57. Hagberg JM, Wilund KR, Ferrel R (2000) APOE gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 4:101–104
  58. Schaefer JR, Sattler AM, Hackler B et al (2004) Hyperlipidemia in patients with apolipoprotein E2/E2 phenotype: apolipoprotein A5 S19 W mutation as a cofactor. Clin Chem 50:2214
  59. Hubacek JA, Horinek A, Skodova Z et al (2005) Hypertriglyceridemia: interaction between APOE POA5 variants. Clin Chem 51:1311–1313
• 作者单位：1. Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Ant么nio Carlos avenue, 6627, Belo Horizonte, MG 31270-901, Brazil2. S茫o Vicente de Paulo Ambulatory Pediatrics, Clinical Hospital of Federal University of Minas Gerais, Belo Horizonte, Brazil3. Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Animal Anatomy, Morphology and Histology
  Animal Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-4978

文摘

Apolipoprotein A5 (APOA5) and apolipoprotein E (APOE) play important roles in the metabolism of cholesterol and triglycerides. The aim of this study was to determine the allelic and genotypic distributions of the APOA5-1131T>C (rs 662799) and the APOE HhaI polymorphisms and to identify the association of both individual and combined APOA5–APOE genetic variants and the risk for dyslipidemia in children and adolescents. We genotyped 53 dyslipidemic and 77 normolipidemic individuals. The total cholesterol, triglycerides and HDL cholesterol were determined enzymatically. For APOA5 polymorphism, the presence of the allele C confers an individual risk for dyslipidemia (OR = 2.38, 95% CI = 1.15–4.89; P = 0.018). No significant differences were observed for lipid parameters among the APOA5 groups, except for a higher value of HDLc (P = 0.024) in C-carriers. The allelic and genotypic frequencies of APOE polymorphism were similar between groups and did not increase the susceptibility for dyslipidemia. None of the combined APOA5–APOE polymorphisms increased risk for dyslipidemia. We demonstrated an association between APOA5-1131T>C polymorphism and dyslipidemia in children and adolescents. This finding may be useful to guide new studies with genetic markers down a path toward a better characterization of the genetic risk factors for dyslipidemia and atherosclerotic diseases.